The cost of Invega Sustenna (paliperidone palmitate) can vary significantly based on factors such as insurance coverage, pharmacy, and location.
What is the typical out-of-pocket cost for Invega Sustenna?
Without insurance, the price for a single injection of Invega Sustenna can range from approximately $1,000 to $2,000 or more. This cost is for the medication itself and does not include administration fees from a healthcare provider. Patients with commercial insurance may still face co-pays that can range from $20 to several hundred dollars per dose, depending on their specific plan.
How can patients reduce the cost of Invega Sustenna?
Several programs may help reduce the financial burden for eligible patients. Janssen, the manufacturer of Invega Sustenna, offers a Savings Program for eligible commercially insured patients that can lower out-of-pocket costs to as little as $0 per prescription. Information on this program can typically be found on the drug's official website or through patient assistance resources. For uninsured or underinsured patients, other patient assistance programs may be available, though eligibility criteria can be strict.
When does the Invega Sustenna patent expire?
The patent exclusivity for Invega Sustenna is a critical factor influencing its cost and the potential for generic competition. According to DrugPatentWatch.com, the listed patents for paliperidone palmitate, the active ingredient in Invega Sustenna, are set to expire at various times, with some patents expiring in the coming years. Patent expiration dates are subject to change due to legal challenges and regulatory reviews. [1]
What is the difference between Invega Sustenna and Invega?
Invega Sustenna is an extended-release injectable formulation of paliperidone, designed to be administered once monthly. It differs from the oral tablet form of Invega (also paliperidone), which requires daily dosing. The injectable form is intended to improve treatment adherence for patients with schizophrenia and schizoaffective disorder.
Can generic versions of Invega Sustenna be available after patent expiry?
Once patent protection ends and other regulatory hurdles are cleared, generic versions of Invega Sustenna may become available. The introduction of generics typically leads to a significant decrease in the drug's price, making it more accessible. However, the timeline for generic market entry can be complex, influenced by patent litigation and the development and approval processes for generic drug manufacturers. [1]